

---

DIGEST

The digest printed below was prepared by House Legislative Services. It constitutes no part of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

---

SB 148 Engrossed

2024 Regular Session

Mizell

Present law provides certain requirements for implementation of step therapy or fail first protocols used by any commercial health coverage plan.

Present law requires health coverage plans that restrict medications through step therapy or fail first protocol to have a process for the prescribing practitioner to request to override the restriction if certain criteria are met.

Proposed law retains present law.

Proposed law further authorizes a prescribing practitioner to request an override if the health coverage plan's required prescription drug for postpartum depression under a step therapy or fail first protocol is not indicated by the U.S. Food and Drug Administration for postpartum depression on the prescription drug's approved labeling.

(Adds R.S. 22:1053(C)(6))

Summary of Amendments Adopted by Senate

Committee Amendments Proposed by Senate Committee on Health and Welfare to the original bill

1. Deletes the prohibitions against health coverage plans and managed care organizations using step therapy or first fail protocol for the treatment of postpartum depression.
2. Deletes the requirement for health coverage plans and managed care organizations to cover screening for postpartum depression or related mental health disorders.
3. Deletes provisions regarding effectiveness.
4. Adds requirement that a prescribing practitioner can request an override for postpartum depression if certain conditions are met.

Summary of Amendments Adopted by House

The Committee Amendments Proposed by House Committee on Insurance to the engrossed bill:

1. Modify proposed law to authorize a prescribing practitioner to request an override if the required prescription drug for postpartum depression under a step therapy or fail first protocol is not indicated by the U.S. Food and Drug Administration for postpartum depression on the prescription drug's approved labeling.